Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc.
31 March 2020 - 11:45PM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform, today announced
that it appointed Jerome Zeldis, M.D., Ph.D as Executive Chair of
ViralClear Pharmaceuticals, Inc., a new division within its
majority-owned subsidiary NeuroClear Technologies, Inc., which
recently acquired the rights to develop a novel pharmaceutical to
treat Coronavirus Disease 2019 (COVID-19).
Jerome (“Jerry”) Zeldis, M.D., Ph.D brings extensive life
sciences experience gained primarily through his career at Celgene,
Inc. He previously served as Chief Executive Officer of Celgene
Global Health and Chief Medical Officer of Celgene Corporation, a
publicly traded, fully integrated biopharmaceutical company, where
he was employed for nearly 20 years, starting in 1997. Celgene
Corporation was recently acquired by Bristol Myers-Squibb
(NYSE:BMY]. Dr. Zeldis currently serves as a Director of
BioSig.
“From the moment we learned that we may have a possible solution
to help address this global pandemic, we have been working
tirelessly to bring this pharmaceutical to patients,” commented Dr.
Zeldis. “I look forward to pursuing development of Vicromax(tm) and
contributing my knowledge and expertise to this important
initiative.”
From 2016 to recently, Dr. Zeldis served as Chief Medical
Officer and President of Clinical Research, Medical Affairs Drug
Safety, Quality, and Regulatory at Sorrento Therapeutics, Inc.. He
attended Brown University for an AB, MS, followed by Yale
University for an M Phil, MD, PhD in Molecular Biophysics and
Biochemistry. Dr. Zeldis trained in Internal Medicine at the UCLA
Center for the Health Sciences and in Gastroenterology at the
Massachusetts General Hospital and Harvard Medical School. He was
Assistant Professor of Medicine at the Harvard Medical School,
Associate Professor of Medicine at University of California, Davis,
Clinical Associate Professor of Medicine at Cornell Medical School
and Professor of Clinical Medicine at the Robert Wood Johnson
Medical School in New Brunswick, New Jersey. Dr. Zeldis is a named
inventor on 43 US patents, has published 122 peer reviewed articles
and 24 reviews, book chapters and editorials.
In a preliminary internal review, the orally administered,
broad-spectrum anti-viral agent Vicromax(tm) demonstrated strong
activity against COVID-19 in cell cultures in laboratory testing.
In this analysis, Vicromax(tm) was added to a tissue culture assay
for SARS-CO-2 coronavirus (the causative agent for COVID-19) and an
anti-viral effect was observed, which led to a reduction of over
90% of infectious viruses. The Company intends to pursue
development of this agent for the treatment of COVID-19 through
FDA-approved clinical trials.
The product candidate already completed Phase I and three Phase
II clinical trials involving over 134 subjects for indications
other than COVID-19, and underwent extensive animal testing and
human clinical experience. The Company expects that Vicromax(tm)
might be used alone or in a combination with other anti-viral
agents or immune modulators.
“We know Dr. Zeldis as an accomplished medical scientist and a
talented Board member, and we are honored that he accepted this
important role. I have personally worked closely with Jerry for
years and highly value his unique talents. As we battle the
biggest healthcare crisis in a generation, we need world-class
scientific and business leadership to find a solution which would
take the pressure off our healthcare resources. BioSig remains
fully committed to expanding clinical footprint in
electrophysiology, and we look forward to working with Dr. Zeldis
and his team in this new capacity,” stated Kenneth L. Londoner,
Founder, Chairman and CEO of BioSig Technologies, Inc.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About NeuroClear TechnologiesNeuroClear
Technologies, a majority-owned BioSig subsidiary, is a medical
technology company focused on electroneurogram recordings. The
Company aims to address some of the biggest challenges of
bioelectronic medicine devices through targeted stimulation and
feedback loops for optimal therapy delivery.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise
Shareholder contact:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
Media contact:
High Lantern Group
Drew Holzapfel (US)
dholzapfel@highlanterngroup.com
215-515-2353
Mario Ottiglio (International)
mottiglio@highlanterngroup.com
+41 79 538 8624
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2024 to May 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From May 2023 to May 2024